

Press Release

ProStrakan Group plc

ProStrakan's Sancuso outlicensed by Solasia in Asia

Galashiels, UK, 3 March 2010: ProStrakan Group plc (LSE: PSK), the international specialty pharmaceutical company, today announces that Solasia Pharma K.K., the Group's partner for Sancuso in various Asian markets, has entered into a License Agreement with Kyowa Hakko Kirin, granting Kyowa Hakko Kirin the exclusive right to market and sell Sancuso® in Taiwan, Hong Kong, Singapore and Malaysia.

Sancuso is a transdermal patch that delivers granisetron, an established 5-HT₃ receptor antagonist, steadily into the bloodstream for several days, helping to prevent the side-effects of nausea and vomiting in patients undergoing chemotherapy for up to five consecutive days, without the need for daily injections or having to swallow pills.

Sancuso received a marketing authorisation from the US Food and Drug Administration (FDA) in September 2008 and was launched in the US in November 2008.

Under the terms of the agreement announced today, Solasia will receive upfront, regulatory and sales milestones from Kyowa Hakko Kirin, who will be responsible for all

commercialisation activities in these territories, which will in turn lead to future income for ProStrakan.

Dr Wilson Totten, Chief Executive of ProStrakan, said:

“The further roll-out of Sancuso demonstrates how our strategy of extending the reach of our medicines through our extensive partnering network can generate a valuable ongoing income stream for ProStrakan.”

Ends

For further enquiries, please contact:

ProStrakan	+44 (0) 1896 664000
Dr Wilson Totten, Chief Executive	
Allan Watson, Chief Financial Officer	
Callum Spreng, Corporate Communications	
Brunswick Group	+44 (0) 20 7404 5959
Jon Coles / Justine McIlroy	

About ProStrakan:

ProStrakan Group plc is a rapidly growing specialty pharmaceutical company engaged in the development and commercialisation of prescription medicines for the treatment of unmet therapeutic needs in major markets.

ProStrakan's head office is located in Galashiels in Scotland. The company's development capabilities are centered in Galashiels and Bedminster, New Jersey, USA. Sales and marketing of ProStrakan's portfolio of products are handled by commercial subsidiaries in the UK, US, France, Germany, Spain, Italy and other EU countries.

www.prostrakan.com

About Solasia

Solasia Pharma K.K. (Tokyo, Japan) was formed in November 2006 by MPM Capital and Itochu Corporation to address unmet needs for important new Western oncology therapies throughout Asia. Our mission is to expedite patient access to unique oncology therapies through aggressive development and specialized commercialization throughout Japan, China and other Asian countries. In May 2008, Solasia acquired Asia rights to Sancuso (granisetron transdermal patch) from ProStrakan Group plc. To date, Solasia has raised approximately \$16 million in Series A financing.